Page last updated: 2024-10-24

positive regulation of macrophage migration inhibitory factor signaling pathway

Definition

Target type: biologicalprocess

Any process that activates or increases the frequency, rate or extent of macrophage migration inhibitory factor signaling pathway. [GOC:obol]

Positive regulation of macrophage migration inhibitory factor (MIF) signaling pathway involves a complex cascade of molecular events that ultimately lead to enhanced MIF-mediated cellular responses. MIF, a pro-inflammatory cytokine, exerts its effects by binding to its cognate receptor, CD74, and triggering downstream signaling pathways. This process is tightly regulated at multiple levels, ensuring appropriate activation and preventing aberrant inflammation. Key steps in the positive regulation of MIF signaling include:

1. **MIF Production and Release:** The production of MIF is induced by various stimuli, including inflammatory signals, stress, and pathogen recognition. Cells like macrophages, T cells, and endothelial cells synthesize and release MIF upon activation.

2. **MIF Binding to CD74:** MIF binds to its receptor CD74, a type I transmembrane protein expressed on various cell types. This interaction initiates a signaling cascade, leading to downstream effector responses.

3. **Activation of Intracellular Signaling Pathways:** MIF-CD74 interaction activates multiple intracellular signaling pathways, including:
- **ERK1/2 MAP Kinase Pathway:** MIF activates the ERK1/2 MAP kinase pathway, promoting cell survival, proliferation, and migration.
- **JNK Pathway:** MIF can activate the JNK pathway, which is involved in stress responses and apoptosis.
- **p38 MAP Kinase Pathway:** MIF can also activate the p38 MAP kinase pathway, leading to cytokine production and inflammatory responses.
- **PI3K/Akt Pathway:** MIF can activate the PI3K/Akt pathway, which promotes cell survival and inhibits apoptosis.

4. **Transcriptional Regulation:** The activated signaling pathways converge on transcription factors, regulating the expression of genes involved in inflammation, cell survival, and immune responses. For example, MIF can activate NF-κB, a key regulator of inflammatory gene expression, leading to the production of pro-inflammatory cytokines like TNF-α and IL-6.

5. **Positive Feedback Loops:** MIF signaling can also create positive feedback loops, amplifying its own production and enhancing downstream responses. For example, MIF can stimulate the release of additional MIF from neighboring cells, further intensifying the inflammatory response.

6. **Regulation of Immune Cell Functions:** The positive regulation of MIF signaling plays a crucial role in modulating immune cell functions, including:
- **Macrophage Activation:** MIF promotes macrophage activation, leading to enhanced phagocytosis, cytokine production, and antigen presentation.
- **T Cell Proliferation and Differentiation:** MIF can influence T cell proliferation and differentiation, promoting Th1 and Th17 responses.
- **Neutrophil Recruitment:** MIF can attract neutrophils to sites of inflammation, contributing to the innate immune response.

7. **Tissue Repair and Regeneration:** MIF signaling is also implicated in tissue repair and regeneration. It promotes angiogenesis (blood vessel formation) and stimulates the production of growth factors, contributing to wound healing.

In summary, positive regulation of MIF signaling is a complex and multi-faceted process that governs inflammatory responses, immune cell functions, and tissue repair. By enhancing MIF-mediated signaling pathways, cells can mount effective immune responses and promote tissue regeneration.'
"

Proteins (2)

ProteinDefinitionTaxonomy
C-X-C chemokine receptor type 4A C-X-C chemokine receptor type 4 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P61073]Homo sapiens (human)
HLA class II histocompatibility antigen gamma chainAn MHC class II histocompatibility antigen gamma chain that is encoded in the genome of human. [PRO:WCB, UniProtKB:P04233]Homo sapiens (human)

Compounds (12)

CompoundDefinitionClassesRoles
zalcitabinezalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.

Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
pyrimidine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
plerixaforplerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.

plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2
azacycloalkane;
azamacrocycle;
benzenes;
crown amine;
secondary amino compound;
tertiary amino compound
anti-HIV agent;
antineoplastic agent;
C-X-C chemokine receptor type 4 antagonist;
immunological adjuvant
benzylanilinebenzylaniline: major metabolite of antazoline; RN given refers to parent cpd
terephthalamidebenzenedicarboxamide
krh 1636KRH 1636: structure in first source
amd 8664
cyclo(d-tyrosyl-arginyl-arginyl-3-(2-naphthyl)alanyl-glycyl)oligopeptide
amd 070mavorixafor: a derivative of AMD3100; a CXCR4 blockeraminoquinoline
wz 811
crizotinibcrizotinib : A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

Crizotinib: A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER.
3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amineantineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
tn14003TN14003: synthetic antagonist 14-mer peptide inhibiting metastasis in an animal model
pf-06463922lorlatinib : A cyclic ether that is 16,17-dihydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecin-15(10H)-one substituted by methyl groups at positions 2 and 10R, and by cyano, amino and fluoro groups at positions 3, 7 and 12 respectively. It is a small molecule inhibitor of ALK and ROS1 kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer.

lorlatinib: inhibits both anaplastic lymphoma kinase and c-ros oncogene 1 (ROS1) protein
aminopyridine;
aromatic ether;
azamacrocycle;
benzamides;
cyclic ether;
monofluorobenzenes;
nitrile;
organic heterotetracyclic compound;
pyrazoles
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor